person
Annabel M.
- Country
- France
- Department
- #1102: Hôpital Bretonneau département de médecine adulte
Research Overview
assignment
6
Clinical Trials ·
- A Phase II double-blind multi-center, placebo-controlled trial, to assess the efficacy and safety of alpelisib (BYL719) in pediatric and adult patients with Megalencephaly-CApillary malformation Polymicrogyria syndrome (MCAP)
- Efficacy and Safety of Alpelisib in Pediatric and Adult Patients with PIK3CA-Mutated Lymphatic Malformations: A Randomized, Double-Blind, Placebo-Controlled Study
- A Phase 3 Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Upadacitinib in Combination with Topical Corticosteroids in Adolescent and Adult Subjects with Moderate to Severe Atopic Dermatitis
location_city
1
Research Sites
Data & Insights
medical_services
Primary Speciality
Main therapeutic area
handshake
Return Partnerships
Recurring site collaborations
33
Sites with multiple studies
Has run more than one trial at 33 of 142 partner sites.
Specializations
Pediatric Genetic Disorders
Focused on treating rare genetic conditions affecting children, particularly Megalencephaly-CApillary malformation Polymicrogyria syndrome (MCAP) and conditions associated with PIK3CA mutations.
- Developmental Disorders
- Genetic Malformations
- Pediatric Vascular Conditions
Dermatological Conditions
Specializes in managing chronic skin conditions, including moderate to severe atopic dermatitis and alopecia areata in both adolescent and adult populations.
- Inflammatory Skin Disorders
- Autoimmune Hair Loss
- Pediatric Dermatology
Vascular Malformations
Expertise in treating complex vascular anomalies, particularly lingual microcystic lymphatic malformations and lymphatic system disorders.
- Congenital Vascular Anomalies
- Lymphatic System Disorders
- Oral Cavity Malformations
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.